Brief: Soligenix Enters Into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease
01/05/2023 12:42
May 1 (Reuters) - Soligenix Inc SNGX.O :
* SOLIGENIX ENTERS INTO EXCLUSIVE OPTION AGREEMENT WITH SILK
ROAD
THERAPEUTICS FOR RIGHTS TO TOPICAL PENTOXIFYLLINE DESIGNED TO
TREAT BEHÇET'S DISEASE
* SOLIGENIX INC - TERMS OF DEAL WERE NOT DISCLOSED
Source text for Eikon: ID:nPn5HCYkpa
Further company coverage: SNGX.O
((Reuters.Briefs@thomsonreuters.com;))